Dihydroartemisinin (DHA)‐loaded liposomes enhanced the circulation time of Epirubicin and improved its efficacy in different breast cancer cells by reducing Bcl‐2 activity, promoting Beclin‐1 release, and activating Bax. This evidence concerns the gene BECN1 and breast cancer.